ArticlePloS one2025
Investigating the mechanism of oridonin against triple-negative breast cancer based on network pharmacology and molecular docking.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oridonin, a tetracyclic diterpenoid from Rabdosia rubescens (Hemsl.) Hara, exhibits various pharmacological actions, such as anti-tumor, anti-infective, and anti-inflammatory properties. However, the underlying pharmacological effects of oridonin on triple-negative breast cancer (TNBC) are yet to be elucidated. This study aims to examine the molecular mechanism and pharmacological impact of oridonin on TNBC using a network pharmacological strategy. Initially, the pharmacological databases and analysis platforms were employed to identify the potential targets of oridonin using the GeneCards website. The process of standardizing gene names involved the conversion of all target genes using the UniProt database. The acquired data was subjected to identify prevalent target genes. Then, these genes were examined using the STRING website to create a protein-protein interaction (PPI) network. In addition to Gene ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, a molecular docking analysis was conducted to validate the binding conformation between oridonin and the putative target genes. Among the selected 549 genes, 106 genes were found to interact with TNBC. The KEGG study suggested that the underlying mechanism could potentially be linked to the PI3K/Akt signaling pathway and proteoglycans in cancer. Moreover, molecular docking studies indicated that oridonin exhibited the strongest binding affinity with AKT1 (binding energy: -11.40 kcal/mol) and significant associations with other major targets, including EGFR, NFKB1, MAPK1, and SRC. In summary, the resultant findings based on molecular docking and network pharmacology could demonstrate the potential applicability of oridonin for treating TNBC through pathways like PI3K/Akt signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.